文献速递临床试验与 GCP基础与转化研究

别嘌醇对需体外循环心脏手术的危重先天性心脏病新生儿脑与心脏保护(CRUCIAL):一项III期、随机、四盲、安慰剂对照、荷兰多中心试验的研究方案

CeRebrUm and CardIac Protection with ALlopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial.
PubMed 文献 · Trials · 2022-02-23

本研究为III期、随机、四盲、安慰剂对照、荷兰多中心试验,纳入出生后4周内需体外循环心脏手术的危重先天性心脏病新生儿,比较别嘌醇与甘露醇安慰剂对脑损伤复合终点的影响。计划共236例(产前诊断188例),主要终点为术后早期MRI中重度缺血或出血性脑损伤、因病情不稳定无法行术后MRI或体外循环后1个月内死亡。

要点

  • 别嘌醇在产前诊断患儿出生后早期静脉给药2剂,所有患儿围术期给药3剂,每剂20 mg/kg。
  • 主要终点为术后早期MRI中重度缺血或出血性脑损伤、无法行术后MRI或体外循环后1个月内死亡的复合终点。
  • 计划入组236例(产前诊断188例),中期分析在118例(产前诊断94例)时进行,可选因疗效提前终止。

核心结论

  • 该试验将探究出生后即刻及心脏手术前后给予别嘌醇是否减少危重先天性心脏病新生儿中重度缺血和出血性脑损伤,并改善心脏功能与神经发育结局。

研究设计与样本

  • III期、随机、四盲、安慰剂对照、荷兰多中心试验;纳入产前或出生后诊断、需在出生后4周内行体外循环心脏手术的危重先天性心脏病新生儿。

主要发现

  • 尚未报告试验结果;主要终点为术后早期MRI中重度缺血或出血性脑损伤、因病情不稳定无法行术后MRI或体外循环后1个月内死亡的复合终点。

关键数值与推荐

  • 别嘌醇或甘露醇安慰剂静脉给药:产前诊断者出生后早期2剂,所有患儿围术期3剂,每剂20 mg/kg。
  • 计划共236例(产前诊断188例),以证明主要终点发生率在产前组降低20%、出生后组降低9%(把握度80%;总体I类错误控制在5%,双侧)。
  • 中期分析在n=118(产前诊断94例)时进行,可选因疗效提前终止。
  • 次要结局包括术前和术后脑损伤严重程度、白质损伤体积(MRI)、心脏功能(超声心动图)、出生后和术后癫痫活动(aEEG)与区域脑氧饱和度(NIRS)、3月龄神经发育(全身运动)、24月龄运动、认知和语言发育及生活质量,以及别嘌醇的安全性和成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neonates with critical congenital heart disease (CCHD) undergoing cardiac surgery with cardiopulmonary bypass (CPB) are at risk of brain injury that may result in adverse neurodevelopment. To date, no therapy is available to improve long-term neurodevelopmental outcomes of CCHD neonates. Allopurinol, a xanthine oxidase inhibitor, prevents the formation of reactive oxygen and nitrogen species, thereby limiting cell damage during reperfusion and reoxygenation to the brain and heart. Animal and neonatal studies suggest that allopurinol reduces hypoxic-ischemic brain injury and is cardioprotective and safe. This trial aims to test the hypothesis that allopurinol administration in CCHD neonates will result in a 20% reduction in moderate to severe ischemic and hemorrhagic brain injury. METHODS: This is a phase III, randomized, quadruple-blinded, placebo-controlled, multicenter trial. Neonates with a prenatal or postnatal CCHD diagnosis requiring cardiac surgery with CPB in the first 4 weeks after birth are eligible to participate. Allopurinol or mannitol-placebo will be administered intravenously in 2 doses early postnatally in neonates diagnosed antenatally and 3 doses perioperatively of 20 mg/kg each in all neonates. The primary outcome is a composite endpoint of moderate/severe ischemic or hemorrhagic brain injury on early postoperative MRI, being too unstable for postoperative MRI, or mortality within 1 month following CPB. A total of 236 patients (n = 188 with prenatal diagnosis) is required to demonstrate a reduction of the primary outcome incidence by 20% in the prenatal group and by 9% in the postnatal group (power 80%; overall type 1 error controlled at 5%, two-sided), including 1 interim analysis at n = 118 (n = 94 with prenatal diagnosis) with the option to stop early for efficacy. Secondary outcomes include preoperative and postoperative brain injury severity, white matter injury volume (MRI), and cardiac function (echocardiography); postnatal and postoperative seizure activity (aEEG) and regional cerebral oxygen saturation (NIRS); neurodevelopment at 3 months (general movements); motor, cognitive, and language development and quality of life at 24 months; and safety and cost-effectiveness of allopurinol. DISCUSSION: This trial will investigate whether allopurinol administered directly after birth and around cardiac surgery reduces moderate/severe ischemic and hemorrhagic brain injury and improves cardiac function and neurodevelopmental outcome in CCHD neonates. TRIAL REGISTRATION: EudraCT 2017-004596-31. Registered on November 14, 2017. ClinicalTrials.gov NCT04217421. Registered on January 3, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Stegeman R, Nijman M, Breur JMPJ, et al. CeRebrUm and CardIac Protection with ALlopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial. Trials. 2022. PMID: 35197082. doi:10.1186/s13063-022-06098-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。